@article{6d22f7bc2cde4d008d7377922bbf3be5,
title = "Acute renal insufficiency during telavancin therapy in clinical practice-authors' response",
keywords = "Daptomycin-non-susceptible S. aureus, Methicillin-resistant Staphylococcus aureus, Nephrotoxicity, Vancomycin-intermediate S. aureus",
author = "Marcos, {Luis A.} and Camins, {Bernard C.} and Ritchie, {David J.} and Ed Casabar and Warren, {David K.}",
note = "Funding Information: B. C. C. and D. J. R. are on the speaker{\textquoteright}s bureau of Astellas Pharma US, Inc. B. C. C. has received research support from Astellas Pharma US, Inc. D. K. W. has received research support from bioM{\'e}rieux, Sage, Inc., Cubist Pharmaceuticals and 3M Healthcare, and has served as a consultant for 3M Healthcare and Bard, Inc. All other authors: none to declare.",
year = "2012",
month = may,
doi = "10.1093/jac/dks103",
language = "English",
volume = "67",
pages = "1301--1302",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
number = "5",
}